

REFERENCES

- ***Abdel-Fattah MI*** (2000): Comparative study between PGF_{2α} and PGE₁ in induction of abortion during second trimester of pregnancy in cases of I.U.F.D., J Egypt society Obstet Gynecol, vol. 26, 4:5.
- ***Abdel-gadir M, Elbagir M, Eltom A, Eltom M, Berne C*** (2003): Factors effecting perinatal morbidity and mortality in pregnancies complicated by diabetes mellitus, Diabetes Res Clin Pract,60:41.
- ***Adekanmi OA, Purmessur S, Edwards G*** (2001): Intrauterine misoprostol for the treatment of severe recurrent atonic secondary postpartum haemorrhage. Br J Obstet Gynecol; 108:541-542.
- ***Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD*** (1989): Molecular Biology of the cell: 2nd ed. Garland Publishing Inc. New York.
- ***Aghababian KR*** (2006): Essentials of emergency medicine contraception, uncomplicated pregnancy and uncomplicated pregnancy; chp 84: 461-475.
- ***Alan H, Lauren N, Sara H*** (2003): Current textbook in obstetric and gynecologic diagnosis and treatment, early pregnancy risks,9th edition; 1:272-85.
- ***American College of Obstetricians and Gynecologists*** (Feb 2001): Management of early pregnancy loss. Practice Bulletin No. 24.
- ***American College of Obstetricians and Gynecologists*** (Jan 2003): Immunization during pregnancy.Committee Opinion No. 282.
- ***American College of Obstetricians and Gynecologists*** (May 2004): Misoprostol Pharmacokinetics vol.103, no. 5, Part.1.
- ***American College of Obstetricians and Gynecologists*** (Oct 2005): Medical Management of Abortion. Practice Bulletin No.67.

- **American College of Obstetricians and Gynecologists** (May2009): Monday Posters; Pregnancy termination in women with previous cesarean delivery: is misoprostol safe? 99-100.
- **American College of Obstetricians and Gynecologists** (Feb 2009a): Committee opinion on international affairs no. 427, Misoprostol for Post abortion Care 1-4.
- **Anke H** (2006): The safety of misoprostol. International Journal of Gynecology and Obstetrics; 94 (Supplement 2), S149-S150.
- **Anselmo J, Cao D, Karrison T** (2004): Fetal loss associated with excess thyroid hormone exposure. JAMA; 292– 691.
- **Aronsson IA** (2007): Misoprostol pharmacokinetics and effects on uterine contractility and cervical ripening in early pregnancy. From the Department of Woman and Child Health, Division of Obstetrics and Gynecology, Karolinska Institutet, Stockholm, Sweden; 7-9.
- **Aronson JK** (2009): Meyler's Side Effects of Endocrine and Metabolic Drugs; Prostaglandins; 101-135.
- **Aronsson A, Bygdeman M, Gemzell-Danielsson K** (2004): Effects of misoprostol on uterine contractility following different routes of administration. Hum Reprod; 19: 81–4.
- **Aronsson A, Ulfgren A, Stabi B, Stavreus-Evers A, Gemzell-Danielsson K** (2005): The effect of orally and vaginally administrated misoprostol on inflammatory mediators and cervical ripening during early pregnancy: Contraception; 72: 33–9.
- **Ashok PW, Penney GC, Flelt GM, et al** (2004): An effective regimen for early medical abortion: a report of 2000 consecutive cases. Hum Reprod; 13:2962-5.
- **Austin J, Ford MD, Rouse A, Hanna E** (1997): Acute intravaginal misoprostol toxicity with fetal demise.J Emerg Med; 15:61–4.

- **Autry A, Jacobson G, Sandhu R, Isbill K** (1999): Medical management of non-viable early first trimester pregnancy Int J Gynecol Obstet; 67:9-13.
- **Ayres-de-Campos D, Teixeira-da-silva J, Campos I et al** (2000): Vaginal misoprostol in the management of first trimester missed abortions. Int. J. Gynecol Obstet; 71 (1): 53-57.
- **Ayudhaya NPO, Herabutya Y, Chanrachakul B , Ayuthaya NNI, et al** (2006): A Comparison of the Efficacy of Sublingual and Oral Misoprostol 400 Microgram in the Management of Early Pregnancy Failure: A Randomized Controlled Trial; J Med Assoc Thai vol. 89 Suppl. 4.
- **Azziz AR, Morgaria DP** (2006): Obstetrics and gynecology: cases, questions, and answers; recurrent pregnancy loss; 205-7.
- **Azlin Nor MI, H. S. N. A. Abdulla, Zainul RM, & Jamil AM** (2006): Misoprostol (alone) in second trimester terminations of pregnancy: As effective as Gemeprost? Journal of Obstetrics and Gynaecology; August; 26(6): 546 – 549.
- **B-Lynch C, Bellad BM, Goudar S** (2006): A textbook of postpartum hemorrhage: a comprehensive guide to evaluation, management and surgical intervention; Misoprostol: theory and practice; 114-27.
- **Banatvala JE, Brown DW** (2004): Rubella. Lancet; 363:1127.
- **Barash Arnold JB, Jonathan DK** (2009): Clinical Anesthesia: occupational health; chp. 3: 57-82.
- **Barclay CG, Brennand JE, Kelly RW, Calder AA** (1993): Interleukin-8 production by the human cervix. Am J Obstet Gynecol; 169(3):625-31.

- **Bartley J, Baird DT** (2002): A randomized study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. *BJOG*; 109:1290–1294.
- **Bebbington MW, Rent N, Lim K, Gagnon A, Delisle MF, Tessier F, Wilson RD** (2002): A randomized controlled trial comparing two protocols for the use of misoprostol in midtrimester pregnancy termination. *Am J Obstet Gynecol*, 187:853.
- **Beckmann RC, Barbara MB, William N H, Frank WL, et al** (2009): *Obstetrics and Gynecology* 6th edition in collaboration with ACOG; Ectopic pregnancy and abortion chp.13:141-151.
- **Bennett PR, Henderson DJ, Noore GE** (1992): Changes in expression of the cyclooxygenase gene in human fetal membranes and placenta with labor. *Am J Obstet Gynecol*; 167:212-6.
- **Benson BC, Bluth IE, Chaitali SS, Ashok AB** (2008): *Ultrasonography in obstetrics and gynecology: a practical approach to clinical Problems; estimating fetal gestational age*; Thieme medical inc. 2nd ed: chp.12; 133-42.
- **Berer. Marge** (2005): Medical Abortion Fact Sheet. *Reproductive Health Matters*; 13(26):20–24.
- **Bergström S, Carlsson LA, Weeks JR** (1968) :The prostaglandins: A family of biologically active lipids. *Pharmacological reviews*; 30(1):1-48.
- **Bernstein A, Peter M, and Lev Kandinos** (2004): Use of misoprostol for labor induction in patients with asthma. *Medscape*. <http://www.medscape.com/>
- **Bique C, Usta M, Debora B, Chong E, Westheimer E, Winikoff B** (2007): Comparison of misoprostol and manual vacuum aspiration

for the treatment of incomplete abortion. *Int J Gynaecol Obstet*; 98: 222–6.

- **Blanchard K, Shelley C, Beverly W, Gayle G, Ghazala K, and Caitlin S** (Feb 2002): Misoprostol for Women's health vol. 99, no. 2, American College of Obstetricians and Gynecologists; 316-22.

- **Blanchard K, Taneepanichskul S, Kiriwat O, Sirimai K, Svirojana N, Mavimbela N, et al** (2004): Two regimens of misoprostol for treatment of incomplete abortion. *Obstet Gynecol*; 103:860-5.

- **Bluth IE** (2008): Ultrasound; A practical approach to clinical problems; First trimester pain or bleeding or both; 89-95.

- **Bond GR and Zee Van A** (1994): Overdosage of misoprostol in pregnancy. *Am J Obstet Gynecol*; 171:561–2.

- **Brant EW, Helms AC** (2007): Fundamentals of diagnostic radiology. Lippincott Williams & Wilkins:3rd ed; chp38, obstetric ultrasound; 976-88.

- **Brown SE, Toner JP, Schnorr JA, et al** (2001): Vaginal misoprostol enhances intrauterine insemination. *Hum Reprod*, 16:96–101.

- **Bugalho A, Bique C, Almeida L** (1993): The effectiveness of intravaginal misoprostol (Cytotec) in inducing abortion after eleven weeks of pregnancy. *Stud Fam Plann*; 24(5):319-323.

- **Bugalho A, Faundes A, Jamisse L** (1996): Evaluation of the effectiveness of vaginal misoprostol to induce first trimester abortion. *Contraception*; 53 (4): 244-246.

- **Cabezas** (1999): Medical versus surgical abortion. *Int J Gynecol Obstet*; 63:S141-6.

- **Caliskan AM, Rath Head C, Fletcher H, et al** (2003): A comparison of two methods of labor induction with vaginal misoprostol. *Int Gynecol Obstet*; 80(3):271-7.
- **Callahan LT, Aaron BC** (2008): *Blueprints Obstetrics and Gynecology, Early pregnancy complications*. Lippincott Williams & Wilkins: 5th ed: chp.2 p.17-32.
- **Carbonell JL, Varela L, Velozco A, et al** (1997a): The use of misoprostol for abortion at ≤ 9 weeks gestational. *Eur J Contracept Repord Health Care*; 2 (3):181-5.
- **Carbonell JL, Varela L., Velazco A., and Fernimdez C** (1997): The use of Misoprostol for termination of early pregnancy *Contraception*; 55:165-168.
- **Carbonell JL, Varela L, Velazco A, Cabezas E, Tanda R, and Sanchez C** (1998): Vaginal Misoprostol for late first trimester abortion. *Contraception* 57(5):329-33.
- **Carbonell JL, Varela L, Valazco A, et al** (1999): Vaginal misoprostol for abortion at 10-13 weeks gestation. *Eur J Contracept Reprod Health Care*; 4:1, 35-40.
- **Carbonell JL., Varela L, Velazco A, Tanda R, Barambio S, Chami S** (2000): Vaginal misoprostol 600 μ g for early abortion; *The Eur J Contracept Reprod Health Care* ;5 :46–51.
- **Carbonell JL, Velazco A, Rodriguez Y, et al** (2001): Oral versus vaginal misoprostol for cervical priming in first trimester abortion: a randomized trial. *Eur J Contracept Reprod Health Care*; 6(3): 134-40.
- **Carbonell JL, Rodriguez J, Aragon S, Velazco A, Tanda R, Sanchez C, Barambio S, Chami S, Valero F** (2001a): Vaginal misoprostol 1000 μ g for early abortion. *Contraception*; 63(3):131-6.

- **Carbonell JL, Rodri'guez J, Velazco A, Tanda R, et al** (2003): Oral and vaginal misoprostol 800µg every 8 h for early abortion. *Contraception*; 67: 457–462.
- **Carlan SJ, Blust DF, O'Brian W** (2002): Buccal versus intravaginal administration of Misoprostol for cervical ripening. *Am J Obstet Gynecol*; 186:229-33.
- **Carrell DT, Wilcox AL, Lowy L, Peterson C.M, Jones K.P, Erickson L, Campbell B, Branch DW, Hatasaka HH** (2003): Elevated sperm chromosome aneuploidy and apoptosis in patients with unexplained recurrent pregnancy loss. *Obstet Gynecol* 101, 1229-35.
- **Castañeda CS, Izquierdo Puente JC, Leon Ochoa RA, Plasse TF, Powers BL, Rayburn WF** (Sep2005): "Misoprostol dose selection in a controlled-release vaginal insert for induction of labor in nulliparous women." *AJOG*, 193 (3Pt2).
- **Castaneda R, Lechuga D, Ramos R.I, Magos C, Orozco M, Martinez H** (2002): Endemic goiter in pregnant women: utility of the simplified classification of thyroid size by palpation and urinary iodine as screening tests. *BJOG*; 109:1366–72.
- **Castleman L, Mann C** (2002): Manual vacuum aspiration (MVA) for uterine evacuation: Pain management. Chapel Hill, NC: Ipas.
- **Castleman LD, Oanh KT, Hyman AG, Thuy le T, Blumenthal PD** (2006): Introduction of the dilation and evacuation procedure for second trimester abortion in Vietnam using manual vacuum aspiration and buccal misoprostol. *Contraception*; 74(3):272- 6.
- **Celik H and Sapmaz E** (2003): Use of a single preoperative dose of misoprostol is efficacious for patients who undergo abdominal

myomectomy. University of Firat (Euphrates), Faculty of Medicine, Departments of Obstet Gynecol, Elazig, Turkey.

- **Challis JRG, Lye SJ** (1994): Parturition. In Knobil E, Neill JD (eds): the physiology of reproduction 2nd ed, Vol.2. New York, Raven, P.985.

- **Chard T and Gibbons GL** (1983): Spurt release of oxytocin during surgical induction of labor. Am J Obstet Gynecol; 149:678.

- **Chattopadhyay KS, Narayanaswamy M, Sayeba A, Chhaya C** (2006): Obstetrics for undergraduates the five fingers; Bleeding in early pregnancy; 55-76.

- **Chawla Surg Lt Cdr S** (2007): A Study of Efficacy of Misoprostol in Missed Abortion; MJAFI; 63: 241-242.

- **Cheung Wai, Tang Oi Shan, Lee H. W. Sharon, Ho Chung Pak** (2003): Pilot study on the use of sublingual misoprostol in termination of pregnancy up to 7 weeks gestation; Contraception; 68: 97–99.

- **Chia KV, Ogbo VL** (2002): Medical termination of missed abortion Obstet Gynaecol; 22: 184-6.

- **Chittacharoen A, Herabutya Y** (2004): Slow fetal heart rate may predict pregnancy outcome in first-trimester threatened abortion. Fertil Steril; 82:227–9.

- **Chittacharoen A, Herabutya Y and Punyavachirap** (2003): A randomized trial of oral and vaginal misoprostol to manage delivery in cases of fetal death. Obstet Gynecol, 101:70.

- **Chong YS, Su LL, Arulkumaran S** (2004): Misoprostol: a quarter century of use, abuse, and creative misuse. Obstet Gynecol Surv; 59: 128-40.

- **Chong Yap-Seng, Selina C, Liang S, Sabaratnam A** (2004): Does the route of administration of misoprostol make a difference? The uterotonic effect and side effects of misoprostol given by different routes after vaginal delivery; Eur J Obstet Gynecol and Reproductive Biology; 113:191–198.
- **Chuck FJ and Huffaker RJ** (1995): Labor induction with intravaginal misoprostol versus intracervical prostaglandin E2 gel. Am J Obstet Gynecol, 173:1137.
- **Chung YK, Chen WH, Yu MH and Liu HS** (2003): Intra-cervical misoprostol and prostaglandin E2 for labor induction. Int J. Gynecol Obstet; 80(1):23-8.
- **Clark S, Blum J, Blanchard K, Galvo A., et al** (2002): Misoprostol use in obstetrics and gynecology in Brazil, Jamaica and the United States. Am J Obstet Gynecol 76:65-74.
- **Clark W, Shannon C, Winikoff B** (2007): Misoprostol for uterine evacuation in induced abortion and pregnancy failure. Expert Rev Obstet Gynecol; 2:67–108.
- **Cnattingius S** (2004): The epidemiology of smoking during pregnancy: smoking prevalence, maternal characteristics, and pregnancy outcomes. Nicotine Tob Res 6 Suppl 2: S125-40.
- **Coleman RA, Grix SP, Head SA and Mallett A** (1994): A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins, 47:151
- **Collins PW** (1990): Misoprostol discovery, development and clinical application Contraception; 53:321-7.
- **Collins PW, Pappo R, Dajani EZ** (1985): Chemistry and synthetic Development of Misoprostol. Dig Dis; 30(11):114-7.

- **Cooper D, Dickson K, Blanchard K, Cullingworths L, Mavimbela N, Von Mollendorf C** (2005): Medical abortion: the possibilities for introduction in the public sector in South Africa *Reproductive Health Matters* 13:35–43.
- **Costa SH** (1998): Commercial availability of misoprostol and induced abortion in Brazil *Int J Gyn Obstet*; 63 (1): 131-9.
- **Craig TB, Ka RW, Kunch WH et al** (2002): Increase prevalence of insulin resistance in women with a history of recurrent pregnancy loss; *Fertil Steril*; 78-487.
- **Crane JM, Young DC, Butt KD, Bennett KA, Hutchens D** (2001): Excessive uterine activity accompanying induced labor; *Obstet Gynecol*; 197(6):962-31.
- **Crane JM, Delaney T, Huchens D** (2003): Oral misoprostol for premature rupture of membranes at term pregnancy. *Am J Obstet Gynecol*; 189(3):720.
- **Creinin MD** (2000): Randomized comparison of efficacy and acceptability of medical versus surgical abortion. *Obstet Gynecol* 95:s83.
- **Crenin M, Aubeny E** (2004): Medical abortion in early pregnancy, in *A Clinician's guide to medical and surgical Abortion*, P. Stubblefield, Editor., Churchill Livingstone :New York.p.91-106.
- **Cunningham FG, Norman FG, Kenneth JL, Larry CG, John CH, Katharine DW** (2005): *Williams Obstetric textbook*, 22th ed McGraw-Hill (U.S.A); Abortion ;(1)232-52.
- **Cunningham FG, Norman FG, Kenneth JL, Larry CG, John CH, Katharine DW** (2009): *Williams Obstetric textbook*, 23th edition, McGraw-Hill (U.S.A); Abortion ;(3)215-38.

- **Cytotec® (misoprostol) package insert** (April 2002). Chicago, IL: G.D. Searle & Co.
- **Daftary N. Shirish, Desai V. Shyam, Dikshit A. Sameer** (2007): Selected Topics in Obs / Gyn for postgraduates; medical termination of pregnancy 118-29.
- **Damyanti Sharma, Savita RS, Rani X X** (2007): Sublingual misoprostol in management of missed abortion in India; Tropical Doctor Journal; January; 37:39-41.
- **Dao B, Blum J, Thieba B, Raghavan S, Ouedraogo M, Lankoande J, et al** (2007): Is misoprostol a safe, effective and acceptable alternative to manual vacuum aspiration for postabortion care?; Results from a randomized trial in Burkina Faso, West Africa. BJOG; 114:1368–75.
- **Darwish AM, Ahmed AM, Mohamed AM** (2004): Cervical priming before operative hysteroscopy: a randomized comparison of laminaria vs misoprostol, Human Reprod; 19:2391-4.
- **Davis AR, Rabilotto CM, Westhoff CL, Forman S, Zhang J** (2004): Bleeding patterns after vaginal misoprostol for treatment of early pregnancy failure. Hum Reprod; 19: 1655-8.
- **Davis AR, Hendlish SK, Westhoff C, Frederick MM, Zhang J, Gilles JM, et al** (2007): Bleeding patterns after misoprostol vs surgical treatment of early pregnancy failure: results from a randomized trial. Am J Obstet Gynecol; 196:31.e1–31. e7
- **DeCherney HA, Lauren N, Goodwin TM et al** (2006): The 10th edition of Current Diagnosis & Treatment in Obstetrics & Gynecology. Mc Grow-Hill.10th ed: Chp.14: Early pregnancy risks; Spontaneous abortion 259-272.

- **Delvaux, Thérèse, and Christiana Nöstlinger** (2007): Reproductive choice for women and men living with HIV: Contraception, abortion and fertility. *Reproductive Health Matters*, 15(29 Supplement):46-66.
- **Demetroulis C, Saridogan E, Kunde D, Naftalin AA** (2001): A prospective randomized control trial comparing medical and surgical treatment for early pregnancy failure. *Hum Reprod*; 16:365-9.
- **Desai Pankaj** (2007): Recent trends in Obstetrics and Gynecology; monitoring early pregnancy; 1-15.
- **Dickinson JE, Evans SF** (2003): A comparison of oral misoprostol with vaginal misoprostol administration in second-trimester pregnancy termination for fetal abnormality. *Obstet Gynecol*; 101:1294–1299.
- **Dickinson JE, Evans SF** (2002): The optimization of intravaginal misoprostol dosing schedules in second-trimester pregnancy termination. *Am J Obstet Gynecol*; 186:470–474.
- **Edmonds DK, Joanne T, Roy GF** (2007): DEWHURST'S Textbook of Obstetrics & Gynecology. Blackwell Publishing: 7th ed: Spontaneous miscarriage; 12: 94-100.
- **Elhassan EM, Nasr AM, Adam I** (2007): Sublingual compared with oral and vaginal misoprostol for labor induction. *Int J Gynecol Obstet*; 97:153–4.
- **El-Makhzangy MI and Hegab MH** (2009): Oral versus rectal misoprostol in the treatment of menorrhagia. *Bull.Alex.Fac.Med*; 45 no.4.
- **El-Refaey H** (1995): Misoprostol: uterotonicity revealed or the place of misoprostol in the evacuation of the human pregnant uterus. *Fertility Control Reviews*; 4:19-21.

- **Elsheikh A, Antsaklis A, Mesogitis S, Papantoniou N, Rodolakis A, Vogas E, Michalas S** (2001): Use of misoprostol for termination of second trimester pregnancies. *Arch Gynecol Obstet*; 265(4):204-6.
- **Eng NS and Guan AC** (1997): Comparative study of intravaginal misoprostol with gemeprost as an abortifacient in second trimester missed abortion. *Aust NZ J Obstet Gynecol*; 37:3,331-4.
- **Evans T. Arthur, Charles C. Coddington, Richard O. Jones** (2007): *Manual of obstetrics; pregnancy loss and spontaneous abortion*; 111-124.
- **Ezegwui HU** (2006): Uterine rupture in a primigravida when misoprostol was used for induction of labor and subsequent successful pregnancy outcome; *J Obstet Gynecol*; 26 (2):160 -161.
- **Fadalla A, Mirghani A** (2004): Oral misoprostol vs vaginal misoprostol for termination of pregnancy with intrauterine fetal demise in the second-trimester. *Int J Gynecol Obstet, Suppl*; 86 (1): 52–3.
- **Fekih Myriam, Fathallah Khadija, Lassad BR, Bouguizane Sassi, et al** (2010): Sublingual misoprostol for first trimester termination of pregnancy; *Int J Gynecol Obstet*; 109: 67–70.
- **Flett AG and Templeton SA** (2007): Termination of pregnancy; in *Edmonds D. Keith Dewhurst's Textbook of Obstetrics & Gynaecology*. Blackwell Publishing; 7th ed: 318-27.
- **Gracia CR, Sammel MD, Chittams J, et al** (2005): Risk factors for spontaneous abortion in early symptomatic 1st trimester abortion; *Obstet Gynecol*; 106:993-96.
- **Gautam R and Agrawal V** (2003): Early medical termination of pregnancy with methotrexate and misoprostol in lower segment cesarean section cases. *Obstet Gynecol*, 29:251.

- **Gemzell-Danielsson K** (2003): Low-dose mifepristone blocks pregnancy by altering ovarian function, *Contraception*; 68:471.
- **Gemzell-Danielsson K, Marions L, Rodriguez A, Spur B.W, Wong PYK, Bygdeman M** (1999): Comparison between oral and vaginal administration of misoprostol on uterine contractility. *Obstet Gynaecol*; 93: 275–80.
- **Ghorab MN and El Helw BA** (1998): Second trimester termination of pregnancy by extra amniotic prostaglandin F2 alpha or endocervical misoprostol. A comparative study. *Acta Obstet Gynecol Scand*; 77 (4):429-432.
- **Gibert A and Reid R** (2001): A randomized trial of oral versus vaginal administration of misoprostol for the purpose of mid-trimester termination of pregnancy. *Aust N. Z. J. Obstet Gynecol*; 41(4):407-10.
- **Graziosi GC, Mol B.W, Ankum WM, Bruinse HW** (2004): Management of early pregnancy loss. *Int J Gynaecol Obstet*; 86: 337–46.
- **Gibbs SR and Davis KJ** (2008): Obstetric and perinatal infection in *Gibbs S. Ronald, David N. Danforth, Beth Y Karlan, Arthur F Haney, et al* :Danforth's obstetrics and gynecology;10th ed; Lippincott Williams & Wilkins (U.S.A);chp.19,; 345-465.
- **Gilstrap C, Cunningham FG, VanDorsten JP, Gary DV** (2002): Pregnancy termination: first and second trimester; *Operative Obstetrics*; chp-30: 535-62.
- **Goldberg BB, McGahan PJ, Lyndon MH** (2008): Diagnostic ultrasound; chp-40 fetal measurements 1069-98.
- **Goldenberg RL, Thompson C** (2003): The infectious origins of stillbirth. *Am J Obstet Gynecol*; 189:861.

- **Goldstein SR, Jacot FR, Poulin C** (1999): Documenting pregnancy and gestational age. A clinician's guide to medical and surgical abortion Churchill Livingstone: 39-54.
- **Gonzalez JA, Carian SJ and Alverson MW** (2001): Outpatient second trimester pregnancy termination. *Contraception*; 63(2): 89-93
- **Grimes DA, Creinin MD** (2004): Induced abortion: an overview for internists. *Annals of Internal Medicine*; 140 (8):620-626.
- **Guerrero and colleagues** (2004): Use of direct latex agglutination testing of selective broth in the detection of group B streptococcal carriage in pregnant women. *Eur J Clin Microbial Infect Dis*, 23:61.
- **Gülmezoglu AM, Forna F, Villar J** (2002): Prostaglandins for prevention of postpartum hemorrhage (Cochrane Review). In: *The Cochrane Library*, Issue2. Oxford, U.K.
- **Gun I, Salman MC** (2008): Safety and efficacy of sublingual misoprostol in first trimester medical abortion *Balkan Military Medical Review* 11, 11-14.
- **Gupta B, Jain V, Aggarwal N** (2006): Rectal misoprostol versus oxytocin in the prevention of postpartum hemorrhage - a pilot study. *Int J Gynaecol Obstet*; 94:S139-40.
- **Hamoda H, Ashok PW, Dow J** (2003): A pilot study of mifepristone in combination with sublingual or vaginal misoprostol for medical termination of pregnancy up to 63 days gestation. *Contraception*; 68:335–8.
- **Hartmann** (2004): Small benign tumors may be linked with increased risk of miscarriage. *Arch Pathol Lab Med*. 128:643.
- **Henriet L and Kaminski M** (2001): Impact of induced abortions on subsequent pregnancy outcome: the 1995 French national perinatal survey. *Br J Obstet Gynaecol*; 108: 1036–42.

- **Herabutya Y and O-Prasersawat P** (1998): Second trimester abortion using intravaginal misoprostol. *Int J Obstet Gynecol*, 60:161.
- **Herabutya Y, Chanrachakul B, Punyavachira P** (2000): Vaginal misoprostol in termination of second trimester pregnancy. *J Obstet Gynaecol Res*; 26:121-5.
- **Herabutya Y, Chanrachakul B, Punyavachira PC** (2001): Second trimester pregnancy termination: a comparison of 600 and 800µg of intravaginal misoprostol. *J Obstet Gynaecol Res*; 27:125-8.
- **Herabutya Y, Chanarachakul B, Punyavachira PC** (2003): induction of labor with vaginal misoprostol for second trimester termination of pregnancy in the scarred uterus. *Int J Obstet Gynecol*, 83:293.
- **Herndon J, Strauss LT, Whitehead S, Parker WY, Bartlett L, Zane S** (2002): Abortion surveillance-United States, 1998. *MMWR Surveillance Summaries*; 51(3):1-32.
- **Hill NCW, Selinger M, Jane Ferguson, Mackenzie IZ** (1990): The placental transfer of mifepristone during the second trimester and its influence upon maternal and fetal steroid concentrations. *Br J Obstet Gynaecol*; 97:406–11.
- **Hirabayashi T and Shimuzu T** (2000): Localization and regulation of cytosolic phospholipase A2. *Biochimica et Biophysica Acta*; 1488:124-38.
- **Hofmeyr GJ, Nikodem VC, Jager M** (2001): Randomized assessment of oral misoprostol side effects in the management of third stage of labor. 17th conference on Priorities in Perinatal care in Southern Africa, Aldam, Free State, 3-6 March.

- **Hofmeyr GJ, Gulmezoglu AM** (2003): Vaginal misoprostol for cervical ripening and induction of labor (Cochrane Review). Cochrane library, issue4.
- **Hofmeyr GJ, Metin AG, Natalia N, Verena L, Sandra F & Gilda P** (2009): Misoprostol to prevent and treat postpartum hemorrhage: a systematic review and meta-analysis of maternal deaths and dose-related effects Bull World Health Organ; 87:666–677.
- **Hughes J, Ryan M, Hinshaw K, Henshaw R, Rispin R, Templeton A** (1996): The costs of treating miscarriage: a comparison of medical and surgical management. Br J Obstet Gynaecol; 103:1217-21.
- **Jan ED and Sharon FF** (2003): A comparison of oral misoprostol with vaginal misoprostol administration in second-trimester pregnancy termination for fetal abnormality. Obstet Gynecol; 101 (6):1292-99.
- **Jain JK, Mishell DR Jr** (1994): A comparison of intravaginal misoprostol with prostaglandin E2 for termination of second-trimester pregnancy. New England Journal of Medicine; 331:290-293.
- **Jain JK, Dutton C, Harwood B** (2002): A prospective randomized, double blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Hum Reprod; 17:1477–1482.
- **Jain JK, Meckstroth KR, Mishell DR** (1999): Early pregnancy termination with intravaginal administered sodium chloride solution moistened misoprostol tablets: historical comparison with mifepristone and oral misoprostol. Am J Obstet Gynecol; 181:1386-91.

- **Jauniaux E, Jraham JB, Macklon N, Steegers E** (2008): Textbook of Periconceptional Medicine; Early placental development and pregnancy outcome in Nick S Macklon, Ian A Greer et al: Informa UK; 1st ed: 317-27.
- **Jeppson PC, Park A, Chen CC** (2008): Multivalvular bacterial endocarditis after suction curettage abortion; *Obstet Gynecol* 112-452.
- **Jaye M and Roy H** (1995): Oxytocin to induce labor. *Clin Obstet Gynecol*, 38:232.
- **Jing Song** (2000): Use of Misoprostol in Obstetrics and Gynecology; Review Article-*Obst & Gyn Survey*; 55(8):503-10.
- **Johnson LG, Mueller BA, Daling JR** (May2003): The relationship of placenta previa and history of induced abortion. *Int J Gynecol Obstet*; 81(2):191-198.
- **Jones BA, Teohw TG, Bennett PR** (2003): Drugs which act on the pregnant uterus. *Current Obstet Gynecol* 13, 74–80.
- **Jones JL, Dietz VJ, Power M** (2001): Survey of obstetrician-gynecologists in the United States about toxoplasmosis. *Infect Dis Obstet Gynecol* 9-23.
- **Jasnosz KM, Shakir AM, Perper JA** (1993): Fatal *Clostridium perfringens* and *Escherichia coli* sepsis following urea-instillation abortion. *Am J Forensic med Path* 14:151.
- **Kambiss SM, Hibbert ML, Macedonia C, Potter ME** (2000): Uterine perforation resulting in bowel infarction. *Mil med* 165:81.
- **Karkanis SG, Caloia D, Salenieks ME, Kingdom J, Walker M, Meffe F, et al** (2002): Randomized controlled trial of rectal

misoprostol versus oxytocin in third stage management. J Obstet Gynaecol Can; 24:149-54

- **Keith D, Edward and Grudzinskas JG** (1999): Dewharast's textbook of obstetric and gynecology for postgraduate, miscarriage, ectopic pregnancy and trophoblastic disease, 6th ed; (1)61-66.

- **Kelly RW** (2002): Inflammatory mediators and cervical ripening. J Reprod Immunol; 57:217-24.

- **Keirse M.JNC** (1993): Prostaglandins in preinduction cervical ripening: Meta analysis of world wide clinical experience. J. Reprod Med. 38:89-100.

- **Kerise MJ** (1993a): Oral PGE2 versus intravenous oxytocin for induction. In Enkin MW, Kerise MJ, Renfreur MJ, Neilson IP (eds): pregnancy childbirth module Conchrane database of systemic reviews. Review No 03327. 3 April. 1992. Disc Issue 2-Oxford, Update software.

- **Khan RU and El-Refaey H** (2003): Pharmacokinetics and adverse-effect profile of rectally administered misoprostol in the third stage labour. Obstet Gynaecol; 101:968- 74.

- **Khan RU, El-Refaey H, Sharma S, Sooranna D, Stafford M** (2004): Oral, rectal and vaginal pharmacokinetics of misoprostol. Obstet Gynaecol; 103,866-70.

- **Khazardoost S, Hantoushzadeh S, Madani MM** (2007): A randomized trial of two regimens of vaginal misoprostol to manage termination of pregnancy of up to 16 weeks. Aust and N Z J Obstet Gynecol; 47:226–229.

- **Kiran U, Amin P, Penketh RJ** (2004): Self-administration of misoprostol for termination of pregnancy: safety and efficacy J Obstet Gynecol; 24; 2:155–156.

- **Kishida Y** (2001): Anxiety in Japanese women after elective abortion. *Journal of Obstetric, Gynecological & Neonatal Nursing*; 30(50) 490-495
- **Kurjak A, Kupesic S, Badrldeen A** (2008): Donald School textbook of ultrasound in obstetrics and gynecology; ultrasound evaluation of abnormal early pregnancy in Kurjak A, Chervenak A, et al: 2nd ed: jaypee. India: chp15; 209-29.
- **Lam H, Tang OS, Lee CP** (2004): A pilot-randomized comparison of sublingual misoprostol with syntometrine on the blood loss in third stage of labor. *Acta Obstet Gynecol Scand*. 83(7): 647-50.
- **Langer BR, Peter C, Firtion C, et al** (2004): A randomized trial of oral and vaginal misoprostol for cervical priming before suction termination of pregnancy. *Br Obstet Gynecol*; 103:1117
- **Lapertina EG** (1982): Regulation of arachidonic acid production: role of phospholipases C and A2. *Trends Pharmacol Sci*; 3:115-8
- **Lars Hoj, Placido Cardoso, Birgitte Bruun Nielsen, Lone Hvidman, et al** (October 2005): Effect of sublingual misoprostol on severe postpartum hemorrhage in a primary health centre in Guinea-Bissau: randomized double blind clinical trial *BMJ* vol.331.
- **Latha G. Stead, S. Matthew Stead, Matthew S. Kaufman, Luis F. Suarez** (2006): First aid for the obstetrics & gynecology clerkship, spontaneous abortion: 2nd ed: 137-198.
- **Lecuit and colleagues** (2004): Targeting and crossing of the human maternofetal barrier by *Listeria Monocytogenes*. *Proc National Acad Sci USA*, 101:6152.
- **Lee DTS, Cheung LP, Haines CJ, Cahn KPM, Chung TKH** (2001): A comparison of the psychologic impact and client satisfaction of surgical treatment with medical treatment of

spontaneous abortion: a randomized controlled trial. *Am J Obstet Gynecol*; 185:953-8.

- **Lee VR, Linda AB, Erin K, Karen RM** (2008): Medical care of the pregnant patient: Recurrent pregnancy loss: chp-9: 66-83.

- **Leslie CL** (2004): Regulation of arachidonic acid availability for eicosanoid production. *Biochem. Cell Biol*; 82:1-17.

- **Lewis LE, Samuel CM, Jeannette ES** (2007): Current diagnosis & treatment in family medicine; McGraw-Hill: 2nd ed: chp.16; 173-181.

- **Lix M, Wan J, Xu CF, et al** (2004): Misoprostol in labor induction of term pregnancy: a meta-analysis. *Chin Med. J. (Engl)*. 177(3):449-52.

- **Lumbiganon P, José V, Gilda P, Gülmezoglu AM et al** (2002): Side effects of oral misoprostol during the first 24 hours after administration in the third stage of labor. *BJOG*: 109 (11):1222-26.

- **MacIsaac L, Grossman D, Balistreri E, Darney P** (2000): Early surgical abortion: An alternative to and backup for medical abortion. *Am J Obstet Gynecol*; 183:S76-S83.

- **Major B, Cozzarelli C, Cooper ML, Zubek J, Richards C, Wilhite M** (2000): Psychological responses of women after first-trimester abortion. *Arch General Psych*; 57(8):777-784.

- **Makhlouf AM, Al-Hussaini TK, Habib DM et al** (2003): Second trimester pregnancy termination, comparison of three different methods. *Obstet Gynecol*, 23:407.

- **Martindale** (2002): The complete drug reference textbook in clinical pharmacology, prostaglandins, 33rd ed; 1438:1447.

- **Mathews JE, Mathai M, George A** (2000): Uterine rupture in a multiparous woman during labor induction with oral misoprostol. *Int J Gynaecol Obstet*; 68(1):43–4.
- **Maureen P, Steve L, Lynn B, Phillip GS** (2009): *Management of Unintended and Abnormal Pregnancy: Comprehensive Abortion Care; clinical assessment and U/S in early pregnancy*; Wiley Blackwell:1st ed: chp.6:63 -77
- **McGahan PJ, Goldberg BB** (2006): *Atlas of ultrasound measurements; First trimester obstetric measurements; Embryonic heart rate*; 1-15.
- **McPhee JS, Lawrence MT, Maxine AP** (2007): *Current medical diagnosis and treatment: spontaneous abortion*; 786-789.
- **Meckstroth KR, Whitaker AK, Bertisch S, Goldberg AB, Darney PD** (2006): Misoprostol administered by epithelial routes. *Obstet Gynaecol*; 108,582-90.
- **Mendilcioglu I, Simsek M, Seker PE, et al** (2002): Misoprostol in second and early third trimester for termination pregnancies with fetal anomalies. *Int J Gynecol Obstet*; 79(2): 131-5.
- **Meydanli MM, Caliskan E, burak F, et al** (2003): Labor induction post-term with 25µg vs. 50µg of intravaginal misoprostol. *Int J Gynecol Obstet*; 81 (3): 249-255.
- **Micheal D, Creinin MD, Jill L** (2001): Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomized trial. *Br J Obstet Gynecol*; 108:469-473.
- **Michael R** (2000): *Pharmacology of prostaglandin in drugs facts and comparisons*. St. Louis.A Wolters Kluwer Company; 1140-1.

- **Michael WB, Nancy Kent, Ken Lim, Alain Gagnon, Marie France Delisle, et al** (2002): A randomized controlled trial comparing two protocols for the use of misoprostol in mid trimester pregnancy termination. *Am J Obstet Gynecol*; 187(4):853-7.
- **Middleton T, Schaff E, Fielding SL, Scahill M, Shannon C, Westheimer E, Wilkinson T, Winikoff B** (2005): Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. *Contraception*; 72(5):328-32.
- **Miller EC, George AV, Fawaz E, Jackie HC** (2008): Hysteroscopic roller ball endometrial ablation; 100-10.
- **Miller WC, Ford CA, Morris M** (2004): Prevalence of chlamydial and gonococcal infections among young adults in United States. *TAMA* 291:2229
- **Misra Renu** (2006): *Ian Donald's Practical Obstetric Problem*. BI Publications Pvt. Ltd, New Delhi: 6th ed; Abortion; 19-39.
- **Mitchel MD** (1992): Biochemistry of the prostaglandins: *Prostaglandins*, 6:687.
- **Mohan RA, Phillip RB** (2006): Drugs acting on the pregnant uterus; *Current Obstet Gynecol*; 16: 174–180.
- **Monif RGG, Baker AD, William JL** (2008): infectious Diseases in Obstetrics and Gynecology; Infectious complications associated with legal termination of pregnancy; *chp-64*: 349-53.
- **Moran M, Mozes MF, Maddux MS** (1990): Prevention of acute graft rejection by prostaglandin E1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone. *N Engl J Med*; 322:1183-88.

- **Moreau C, Kaminski M, Ancel PY, Bouyer J, Escande B, Thiriez G** (2005): Previous induced abortions and the risk of very preterm delivery: results of the EPIPAGE study. *British Journal of Obstetrics and Gynaecology*; 112(4):430-437.
- **Moslemizadeh N, Moghadam T. Galini, Peyvandi S** (2009): Evaluation of Vaginal Misoprostol Effect on Pregnancy Rate after Intrauterine Insemination; *Pakistan Journal of Biological Sciences*; vol.12 Issue: 1 64-68
- **Muffley PE, Stitely ML, Gherman RB** (2002): Early intra uterine pregnancy failure: A randomized trial of medical versus surgical treatment. *Am J Obstet Gynecol*; 187 (2): 321-326.
- **Munthall J and Moodley J** (2001): The use of misoprostol for mid-trimester therapeutic termination of pregnancy. *Trop Doct*; 31(9):157-61.
- **Myatt L and Lye ST** (2004): Expression, localization and function of prostaglandin receptors in myometrium. *Prostaglandins Leukot Essent Fatty Acids* 70:137.
- **Nellore V, Mittal S, Dadhwal V** (2006): Rectal misoprostol vs. 15-methyl prostaglandin F_{2α} for the prevention of postpartum hemorrhage. *Int J Gynaecol Obstet*; 94:45-6.
- **Ngai SW, Chan YM, Lui KL, Ho PC** (1997): Oral misoprostol for cervical priming in non pregnant women. *Human Reproduction*, 12:2373
- **Ngai SW, Tang Os Chan YM, HO PC** (2000): Vaginal misoprostol alone for medical abortion up to 9 weeks gestation: efficacy and acceptability. *Hum Reprod*; 15(5); 1159-62.

- **Ngoc NT, Blum J, Westheimer E, Quan TT, Winikoff B** (2004): Medical treatment of missed abortion using misoprostol. *Int J Gynaecol Obstet*; 87:138–42
- **Nugteren DH, Berthuis RK, VanDorp DA** (1966): The enzymatic conversion of all-cis, 8, 11, 14 eicosatrienoic acid into prostaglandin E₁. *Recueil des Travaux chimiques des Pays-Bas* 85:405-419.
- **Nuutila M, Toivonen J, Ylikorkala O, et al** (1997): A comparison between two doses of intravaginal misoprostol and gemeprost for induction of second-trimester abortion. *Obstet Gynecol*; 90:896-900
- **Oakeshott P, Hay P, Hay S, et al** (2002): association between bacterial vaginosis and chlamydial infection and miscarriage before 16 weeks gestation *BMJ* 325:1334.
- **Oboro VO, Tabowe TO** (2003): A randomized controlled trial of misoprostol versus oxytocin in the active management of the third stage of labor. *J Obstet Gynecol*; 23 (1):13-6.
- **Olson DM, Zakart T** (1993): Intrauterine tissue prostaglandin synthesis: regulatory mechanisms seminars; *Reprod. Endocrin* ; 11: 234-6.
- **Ozkaya O, Sezik M, Kaya H, Desdicioglu R, Dittrich R** (2005): Placebo-controlled randomized comparison of vaginal with rectal misoprostol in the prevention of postpartum hemorrhage. *J Obstet Gynaecol Res*; 31:389-93.
- **Padubidri V and Ela A** (2006): Textbook of Obstetrics. BI Publications Pvt. Ltd, New Delhi: chp.10 abnormal pregnancy: abortion; 72-88.
- **Parsons S, Ntunye YM, Walley RL, Wilson JB, Crane JMG, Matthews K, et al** (2004): Rectal misoprostol vs intramuscular

oxytocin in the routine management of the third stage of labour. Proceedings of: 30th British Congress of Obstetrics and Gynaecology, Glasgow.

- **Parsons SM, Walley RL, Crane JMG, Matthews K, et al** (2007): Rectal misoprostol versus oxytocin in the Management of the third Stage of labour. J Obstet Gynaecol Can; 29(9):711–718.

- **Paul ME, Mitchell CM, Rogers AJ, et al** (2002): Early surgical abortion; efficacy & safety .Am J Obstet Gynecol; 187; 407.

- **Pernoll LM** (2001): Early pregnancy complications BENSON & PERNOLL'S handbook of Obstetrics and Gynecology. McGraw-Hill: 10th ed; 295-325.

- **Petraglia AF, Jerome FS, Steven GG** (2007): Preterm birth: mechanisms, mediators, prediction, prevention and interventions: Prostaglandins, Oxytocin and antagonists; 167-77.

- **Pillitteri BA** (2009): Maternal and Child Health Nursing: Care of the Childbearing: Nursing care of a family experiencing a pregnancy complication; chp.21:521-99.

- **Plauche WC, Morison JC, Sullivan MJ** (1992): Surgical obstetrics. W Saunders Company Pennsylvania, 119.

- **Polmear A** (2008): Evidence-based diagnosis in primary care: practical solutions to common problems; bleeding in early pregnancy; 6-14.

- **Pongsatha S and Tongsong T** (2001): Second trimester pregnancy termination with 800µg vaginal misoprostol. J. Med. Assoc Thai; 84(6): 859-63.

- **Pongsatha S, Tongsong T, Suwannawut O** (2001): Therapeutic termination of second trimester pregnancy with vaginal misoprostol. J. Med Assoc Thai; 84 (4): 515-9.
- **Poppe K, Velkeaiers B, Glinioer D, et al** (2008): The role of thyroid autoimmunity in infertility and pregnancy-Nat Clin Pract Endocrinal Metab; 4-394.
- **Porth MC, Ruth H, Charlotte P** (2009): Porth Pathophysiology: Concepts of Altered Health States: structure and function of male genitourinary system; 1027-47.
- **Proctor JA and Hancy AF** (2003): Recurrent first trimester loss is associated with uterine septum but not with bicornuate uterus. Fertile Steril 80:1212
- **Puscheck EE, Pradhan A** (2006): First-Trimester Pregnancy Loss: <http://emedicine.medscape.com/article/266317-overview>
- **Quiroga DR, Esparza AM, Batiza RV, et al** (2002): Vaginal misoprostol in the prevention of postpartum hemorrhage. Gynecol Obstet; 70:572.
- **Rall TW and Schlefer LS** (1985): Oxytocin, PG ergot alkaloids and other drugs, tocolytic agents. In Gilman AG, Goodman LS, Rall TW, Murad F (ed): The pharmacological basis of therapeutics, 7th edition. New York: Macmillan publishing.
- **Ramin KD, Ogburn PL, Danilenko DR, Ramsey PS** (2002): High-dose oral misoprostol for mid-trimester pregnancy interruption; Gynecol Obstet Invest;54(3):176-9.
- **Ramin KD, Ogburn PL, Danilenko DR, et al** (2002a): High dose oral misoprostol for midtrimester pregnancy interruption. Obstet Gynecol; 54:176.

- **Ramsey PS, Savage K, Lincoln T, Owen J** (2004): Vaginal misoprostol versus concentrated oxytocin and vaginal PGE2 for second trimester labour induction. *Obstet Gynecol*; 104: 138-45
- **Revello MG, Gerna G** (2004): Pathogenesis and prenatal diagnosis of human cytomegalovirus infection. *J. Clin Viral* 29:71.
- **Rickert VI, Vaughan RD, Wiemann CM** (2003): Violence against young women. *Contemp Ob/Gyn* 48:30.
- **Robert A, Nezamis JE, Phillips JP** (1967): Discovery of misoprostol. *Am J Dig Dis*; 12:1073-79.
- **Rock Head C, Fletcher H, Reid M, et al** (2003): A comparison of two methods of labor induction with vaginal misoprostol. *Int Gynecol Obstet*; 80(3):271-7.
- **Rodeck CH, Martin JW, Lorenzen J** (2006): Fetal medicine: basic science and clinical practice; Termination of pregnancy: methods, safety and recent development; 341-49.
- **Rouzi AA** (2003): Second-trimester pregnancy termination with misoprostol in women with previous cesarean sections. *Int J Gynaecol Obstet*; 80:317–318.
- **Royal Australian and New Zealand College of Obstetricians and Gynaecologists** (2005): Termination of pregnancy - A resource for health professionals. East Melbourne, Vic.
- **Royal College of Obstetricians and Gynecologists** (2004): The care of women requesting induced abortion. Evidence Based Clinical Guideline Number 7. London, UK.
- **Rubin AE, Howard MR, David AS, Robert MG, et al** (2009): Essentials of Rubin's pathology; infections and parasitic diseases. Lippincott Williams & Wilkins: 5th ed chp.9; 148-95.

- **Ryden MJ, Paul DB, Castelman DL** (2002): Practical gynecology: a guide for the primary care physician :spontaneous abortion in Ryden MJ, Joyce AS, Gerda E, et al: ACP Press (U.S.A):chp.6:158-89.
- **Ryden MJ, Paul DB, Joyce AS, Gerda E, et al** (2009): Practical Gynecology: A Guide for the Primary Care Physician; preconception care. ACP Press: chp.6: 437-460.
- **Saba HN, Anwar S, Ihsanullah M** (2008): Outcome and complications of malaria in pregnancy, Gomal J Medical Sciences; 6(2):98.
- **Saichua C, Phupong V** (2009): A randomized controlled trial comparing powdery sublingual misoprostol and sublingual misoprostol tablet for management of embryonic death or anembryonic pregnancy Arch Gynecol Obstet ;280:431–435.
- **Sanvordeker D** (1981): Stabilization of 16-oxygenated prostanoid acid derivatives. U.S. Patent 4,301,146.
- **Saxena P, Salhan S, Sarda N** (2003): Role of sublingual misoprostol for cervical ripening prior to vacuum aspiration in first trimester interruption of pregnancy. Contraception, 67:213.
- **Schaff EA, DiCenzo R, Fielding SL** (2005): Comparison of misoprostol plasma concentration following buccal and sublingual administration. Contraception; 71(1):22-5.
- **Sengupta S and Arora M** (2007): Gynecology for postgraduates and practitioners 2nd edition; recurrent pregnancy loss chp.14:187-198.
- **Senior J, Marshall K, Sangho R** (1993): In vitro characterization of prostanoid receptors on human myometrium at term pregnancy. Br. J. Pharm 108:501.

- **Shah N, Syed IA, Nusrat HK** (2010): Sublingual versus vaginal misoprostol in the management of missed miscarriage; J Pak Med Assoc; 60(2):21-5..
- **Shankar M, Economides DL, Sabin CA, Tan B, Kadir RA** (2007): Outpatient medical management of missed miscarriage using misoprostol; J Obstet Gynecol, April; 27(3):283–286.
- **Shannon C, Brothers P, Philip NM, Winikoff B** (2004): Infection after medial abortion: a review of the literature. Contraception; 70:183–90.
- **Shelley MJ, David H, Sonia G** (2005): A randomized trial of surgical, medical and expectant management of first trimester spontaneous miscarriage Aust N Z J Obstet Gynecol; 45: 122–127.
- **Shetty A, Danielian P, Templeton A** (2002): Sublingual misoprostol for the induction of labor at term. Am J Obstet Gynecol; 186:72-6.
- **Shetty A, Livingstone I, Acharya Sy, Risc P, et al** (2003): Oral misoprostol (100µg) versus vaginal misoprostol (25 µg) in term labor induction. Acta Obstet Gynecol Scand, 82:103.
- **Shwekerela B, Kalumuna R, Kipingili R, Mashaka N, Westheimer E, Clark W, et al** (2007): Misoprostol for treatment of incomplete abortion at the regional hospital level: results from Tanzania. BJOG; 114:1363–7.
- **Sifakis S, Angelakis E, Vardaki E** (2005): High dose of misoprostol in out patient management of 1st trimester abortion: arch. Obstet Gynecol.:272,183-186.
- **Sloane PD., Lisa MS, Mark HE, Louis BJ** (2008): Essentials of family medicine; Pregnancy prevention, Contraception and Abortion, 5th ed; 395-424.

- **Simpson RK, Creehan AP** (2008): Perinatal nursing; clinical intervention for women in labor; Lippincott Williams & Wilkins: 3rd ed; chp7: 335-61.
- **Singh K, Fong FY, Dong F** (2003): A viable alternative to surgical vacuum aspiration: repeated doses of intravaginal misoprostol over 9 hours for medical termination of pregnancies up to eight weeks; BJOG;110:175-80.
- **Sirimai, KO, Neungton S, Suvanichcati S** (2002): Misoprostol use for therapeutic abortion in siriraj hospital; J. Med. Assoc Thai; 85(4): 416-23.
- **Srisomboon J, Plyamongkol W, Aiewsakul P** (1997): Comparison of intracervical and intravaginal misoprostol for cervical ripening and labor induction in patients with unfavorable cervix. J Med Assoc Thai; 80(3):189-94.
- **Stewart EA** (2001): Uterine fibroids. Lancet 357:293.
- **Strauss FJ, Robert LB, et al** (2009): Yen & Jaffe's Reproductive Endocrinology. Female infertility and abortion: 520-546.
- **Speroff L, Glass RH, Kase NG** (1994): Clinical Gynecologic Endocrinology and Infertility 5thed. Baltimore: Williams and Wilkins; 842.
- **Speroff L, Fritz AM, Kase NG** (2005) : Clinical gynecologic endocrinology and infertility 7th ed; the endocrinology of pregnancy; 259-319.
- **Tamara LC, Aaron BC, Linda GH** (2004): Elective termination of pregnancy: Blueprints Obstetrics & Gynecology 3rd ed; 225-30.

- **Taner CE, Nayki U, Pirci A** (2004): Misoprostol for medical management of first-trimester pregnancy failure: *Int J Gynecol Obstet*; 86:407–408.
- **Tang OS, Wong, KS, Tang, LC, Ho PC** (1999): Pilot study on the use of repeated doses of misoprostol in termination of pregnancy at less than 9 weeks of gestation. *Adv. Contracept.*, 15, 211–216.
- **Tang OS, Ho Pc** (2001): Pilot study on the use of sublingual misoprostol for medical abortion. *Contraception*; 64(5):315-7.
- **Tang OS, Schweer H, Seyberth HW, Lee SWH, Ho PC** (2002a): Pharmacokinetics of different routes of administration of misoprostol. *Hum Reprod*; 17:332–6.
- **Tang OS, Xu J, Cheng L, Lee SWH, Ho PC** (2002b): Pilot study on the use of sublingual Misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks of gestation. *Hum Reprod*; 17(7):1738-40.
- **Tang OS, Miao BY, Lee SWH, Ho PC** (2002c): Pilot study on the use of repeated doses of sublingual Misoprostol in termination of pregnancy up to 12 weeks gestation: efficacy and acceptability. *Human Reprod*; 17(3):654-8.
- **Tang OS, Chan CCW, Ng EHY, Lee SWH, Ho PC** (2003): A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. *Hum Reprod*; 18: 2315–8.
- **Tang OS, Lau WNT, Ng EHY, Lee SWH, Ho PC** (2003a): A prospective randomized study to compare the use of repeated doses of vaginal with sublingual misoprostol in the management of first trimester silent miscarriages. *Hum Reprod*; 18, 1: 176-181.

- **Tang OS, Lau WNT, Chan CCW, Ho PC** (2004): A prospective randomized comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. *Br J Obstet Gynecol*; 111: 1001–5.
- **Tang OS, Charas Y.T.Ong, Ka Yu Tse, Ng EHY, Lee SWH, Ho PC** (September 2005): A randomized trial to compare the use of sublingual misoprostol with or without an additional 1 week course for the management of first trimester silent miscarriage; *Hum Reprod: Advance Access published* 9:1-4.
- **Tang OS, Ho PC** (2006): The pharmacokinetics and different regimens of misoprostol in early first-trimester medical abortion *Contraception* 74: 26– 30.
- **Tang OS, Gemzell-Danielsson K, Ho PC** (2007): Misoprostol: Pharmacokinetic profiles, effects on the uterus and side-effects *Int J Gynecol Obstet*; 99: S160–S167.
- **Tata MH** (2006): Study Package for Medical College Entrance Examinations: Reproduction in humans. Tata McGraw-Hill: 6.1-6. 42.
- **Thomas B and Habeebullah S** (2004): Vaginal misoprostol for medical evacuation of early pregnancy failure. *J Obstet Gynecol India*; 54:340-2
- **Thorpe GM. Jr, Hartmann KE, Shadigian E** (2002): Long-term physical and psychological health consequences of induced abortion: review of the evidence. *Obstet Gynecol Surv*; 58, 67–79
- **Topozada M, Baird BY, Grimes DA** (1995): Termination of pregnancy after 14 weeks, *Modern Methods of inducing abortion*. Oxford, U.K.; Blackwell Science; 70-95

- **Torre S, Giison GJ, Flares S, et al** (2001): Is high-dose misoprostol able to lower the incidence of cesarean section? A randomized controlled trial. *J. Matern Fetal Med*; 10 (2): 85-90.
- **Townsend L and Shelton JA** (1964): Intrauterine death due to fetal erythroblastosis: *Aust N Z J Obstet Gynecol*; 4:85-89.
- **Toy CE, Baker B, Ross JP, et al** (2009): Case files Obstetrics & Gynecology; Approach to spontaneous abortion; 84-88.
- **USDHHS** (2004): The health consequences of smoking: a report of the Surgeon General. Atlanta, Ga, U.S. Dept. of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office of Smoking and Health; Washington, D.C. <http://www.cdc.gov/tobacco/sgr/>.
- **Uzelac, Peter and Sara Garmel** (2007): “Early Pregnancy Risks” *Current Diagnosis and Treatment in Obstetrics and Gynecology*. 10th ed. Ch.14; 356-99; New York: The McGraw-Hill Companies.
- **Vimala N, Mittal S, Kumar S** (2003): Sublingual misoprostol for pre-abortion cervical ripening in first trimester pregnancy termination. *Contraception* 67(4):295-7.
- **Vogel D, Burkhardt T, Rentsch K, Schwee H, Watzer B, Zimmermann R** (2004): Misoprostol versus methylergometrine: pharmacokinetics in human milk. *Am J Obstet Gynecol*; 191: 2168–73.
- **Von Hertzen H, Piaggio G, Huong NT, et al** (2007): Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: a randomised controlled equivalence trial. *The Lancet*; 369: 1904-06.

- **Von Hertzen H, Piaggio G, Daniel W, Nguyen TMH, et al** (2009): Comparison of vaginal and sublingual misoprostol for second trimester abortion: randomized controlled equivalence trial *Human Reproduction*;24(1):106–112.
- **Wagaarachchi PT, Ashok PW, Smith NC, et al** (2002): Medical management of early fetal demise using sublingual misoprostol *BJOG*; 109(4): 462-5.
- **Wagner M** (2005): Off-label use of misoprostol in obstetrics. *BJOG*, 112-266.
- **Wakabayashi M, Tretiak M, Kosasa T, Sharma S, Aeby T, Kamemoto L, et al** (1998): Intravaginal misoprostol for medical evacuation of first trimester missed abortion. *Prim Care Update Ob Gyns*; 5: 176.
- **Warrell AD, John DF , Timothy MC** (2009): *Oxford textbook of medicine; autoimmune disorders in pregnancy*, 443-9.
- **Weeks A, Alia G, Blum J, Winikoff B, Ekwaru P, Durocher J** (2005a): A randomized trial of misoprostol compared with manual vacuum aspiration for incomplete abortion. *Obstet Gynecol*; 106:540–7.
- **Weeks AD, Fiala C, Safar C** (2005): Misoprostol and the debut over off-label drug use *BJOG*, 112-269.
- **Weir MR, Klassen DK, Hall PS** (1991): Minimization of Indomethacin-induced reduction in renal function by misoprostol. *J Clin Pharmacol*; 31:729-35
- **Wilkemeyer MF, Menkari CE, Spon CY** (2002): Peptide antagonists of ethanol inhibition of L1-mediated cell-cell adhesion. *J pharmacol Exp Ther*; 303:110.

- **Wing DA, Jones MM, Rashall A** (1995): Comparison of misoprostol and FGE2 gel for preinduction cervical ripening and labor induction. *Am J Obstet Gynecol*, 172:1804.
- **Winter CT, Sanders C** (2007): *Clinical sonography: a practical guide; First trimester bleeding*; Lippincott Williams & Wilkins: 4th ed; chp39:389-96.
- **Winter E, Wang J, Davies MJ and Norman R** (2002): Early pregnancy loss following assisted reproductive technology treatment. *Hum Reprod* 17(12): 3220-3.
- **Wong CY, Ng EH, Ngai SW, Ho PC** (2002): A randomized, double blind, placebo controlled study to investigate the use of conscious sedation in conjunction with paracervical block for reducing pain in termination of first trimester pregnancy by suction evacuation. *Human Reproduction*; 17(5):1222-1225. 43.
- **Wong KS, Ngai CS, Yeo EL, et al** (2000): A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: a randomized. Comparative trial; *Hum Reprod*; 155 (3): 709-12.
- **Wood SL, Brain PH** (2002): Medical management of missed abortion: A randomized clinical trial. *Obstet Gynecol*; 99:563-6.
- **World Health Organization** (2003): *Safe abortion: technical and policy guidance for health systems*. Geneva.
- **World Health Organization** (2007): *WHO recommendations for the management of the third stage of labor and community perceptions and actions on postpartum hemorrhage: findings from a national survey in Ethiopia*. Geneva.

- **World Health Organization** (2007a): Global and regional estimates of the incidence of unsafe abortion and associated mortality in 2007, 5th ed, Geneva.
- **World Health Organization** (30 April 2009): Technical Report Series of the 17th expert committee on the selection and use of essential medicines: Section 22: Oxytocics and antioxytocics.
- **Xiao** (2003): Misoprostol and mifepristone combine to open the emergency contraception window. *Contraception*, 68:477.
- **Yaacov B, Eyal S, Miriam K** (2004): Misoprostol overdose during the first trimester of pregnancy *Europ J Obstet Gynecol and Reprod Biology*; 115: 108–109.
- **Zieman M, Fong SK, Benowitz NL, Banskter D, Darney PD** (1997): Absorption kinetics of misoprostol with oral or vaginal administration. *Obstet Gynecol*; 90(1):88- 92.
- **Zhang J, Gilles JM, Barnhart K, Creinin M D, Westhoff C, Frederick M M, et al** (2005): A comparison of medical management with misoprostol and surgical management for early pregnancy failure. *N Engl J Med*; 353:761-9.
- **Zhou L and Nilsson A** (2001): Sources of eicosanoid precursor fatty acid pools in tissues. *J Lipid Res*; 42:1521-42.
- **Zlatnik FJ** (1986): Management of fetal death in clinical obstetrics and gynecology *Harpere and Row, Hagerstown P*; 29(2):220-229.
- **Zikopoulos KA, Papnikolaou EG, Kalantaridou SN, et al** (2002): Early pregnancy termination with vaginal misoprostol before and after 42 day gestation. *Hum Reprod*; 17(2): 3079-83.